Haleon (NYSE:HLN) plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group's consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.
The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements. Haleon sells its products through a range of channels including pharmacies, grocery and mass‑market retailers, and increasingly via e‑commerce and direct‑to‑consumer platforms. Its portfolio is positioned around well‑established consumer brands and routine health categories that see frequent, recurring demand.
Since its separation from its former parent, Haleon has operated as an independent, publicly listed company with a focus on building brand strength, expanding global reach and investing in consumer‑led innovation. The business serves markets across Europe, North America, Asia and Latin America, targeting both developed and emerging markets through regional marketing, supply chain footprint and local partnerships.
Strategically, Haleon emphasizes brand marketing, research and development for consumer health formulations, and expanding digital and retail capabilities to meet changing consumer behaviors. The company also highlights commitments to product safety, regulatory compliance and sustainability initiatives as part of its efforts to grow within the global consumer healthcare sector.
